Impressive Presentations by Legend Biotech at the ASH Annual Meeting
Legend Biotech Corporation (NASDAQ: LEGN) recently made headlines by announcing its participation in the 67th Annual American Society of Hematology (ASH) Annual Meeting, where it will present two oral and seven poster presentations focused on CARVYKTI (ciltacabtagene autoleucel, cilta-cel), an innovative therapy for multiple myeloma.
Advancements in CARVYKTI Research
These presentations are poised to bolster the understanding of CARVYKTI, which is the first and only BCMA-targeted CAR-T cell therapy approved for patients with multiple myeloma who have undergone at least one prior treatment. The upcoming ASH event, taking place from December 6-9, 2025, will showcase critical data regarding the efficacy and safety of this treatment, reflecting the continuous innovation within the company.
Highlighting Oral Presentations
Among the oral presentations, Legend Biotech will share significant findings about long-term progression-free survival benefits associated with CARVYKTI in standard-risk relapsed/refractory multiple myeloma. This compelling data will be discussed in a session dedicated to optimizing immune-based therapies in myeloma treatment.
Poster Presentations to Note
In addition, the company's poster presentations will delve into various aspects of CARVYKTI's clinical performance, including the effectiveness of bridging therapy and comparative efficacy analyses with existing treatments. Notably, these insights draw from comprehensive studies that highlight the durability and real-world outcomes of CARVYKTI therapy.
Focus on Allogeneic CAR-T Cell Therapy
Legend Biotech will also present first-in-human data regarding Lucar-G39D, a novel investigational anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy aimed at treating relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). The exploration of this innovative therapy underscores the company's commitment to expanding its treatment pipeline and providing new hope for patients battling hematological malignancies.
Executive Insights on CARVYKTI
Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech, expressed pride in the company's ongoing advancements. He stated, "These presentations further demonstrate the durability of responses and evolving safety profile of CAR-T therapy earlier in the multiple myeloma treatment journey, highlighting our commitment to innovation in this space."
Living Up to Expectations
With over 9,000 patients treated globally, CARVYKTI significantly impacts multiple myeloma care today, catering to a critical need in hematology. The ongoing results from ASH will undoubtedly contribute further to its already established reputation.
Networking and Future Directions
The ASH Annual Meeting serves not only as a platform for presenting key research findings but also as a networking opportunity for professionals dedicated to advancing hematology. Through participation in this prestigious event, Legend Biotech continues to reinforce its role as a leader in the cell therapy landscape.
Frequently Asked Questions
What is CARVYKTI?
CARVYKTI is a BCMA-targeted CAR-T cell therapy approved for treating multiple myeloma in patients who have had at least one prior therapy.
When will Legend Biotech present at ASH?
Legend Biotech will present its findings at the 67th ASH Annual Meeting, scheduled for December 6-9, 2025.
What kinds of presentations will Legend Biotech showcase?
They will showcase two oral presentations and seven poster presentations related to CARVYKTI therapy and novel allogeneic treatments.
How has CARVYKTI been received globally?
CARVYKTI has been made commercially available in 14 countries and has treated over 9,000 patients, indicating a positive reception in the market.
What future developments can we expect from Legend Biotech?
Legend Biotech aims to expand its portfolio of cell therapies and continue to innovate in the treatment landscape for hematological cancers.
